An emerging antiarrhythmic target: late sodium current.
An emerging antiarrhythmic target: late sodium current.
复制标题
DOI：
10.2174/1381612820666141029111729
复制
发表时间：
2014-12
影响因子：
3.1
通讯作者：
T. Bányász;N. Szentandrássy;J. Magyar;Zoltán Szabó;P. Nanasi;Y. Chen-Izu;L. Izu
中科院分区：
文献类型：
--
作者：
T. Bányász;N. Szentandrássy;J. Magyar;Zoltán Szabó;P. Nanasi;Y. Chen-Izu;L. Izu
心脏晚钠电流（INa，L）是近十年来研究的热点。关于电压激活钠电流的持续成分的第一份报告可以追溯到70年代，但早期的研究将这种微小的电流解释为少数通道未能激活的产物，既没有生理学意义也没有病理学意义。近年来，心脏INa，L已成为各种心脏疾病中潜在的主要致瘤机制，引起了临床医生和研究人员的关注。自从雷诺嗪（一种FDA批准的抗心绞痛药物）被证明通过抑制INa，L而成功地抑制心律失常以来，对INa，L的研究活动呈指数增长。本文就心脏晚钠电流及其在生理和病理条件下的调节作一综述。我们将讨论关键证据暗示INa，L作为一个潜在的目标，用于治疗心肌功能障碍和心律失常。
The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.